罚字〔2025〕58 号），认定公司子公司江苏吴中进出口有限公司、中吴贸易发 展(杭州)有限公司、江苏吴中海利国际贸易有限公司通过与浙江优诺德贸易有限 公司等多家关联公司开展无商业实质的贸易业务，虚增营业收入、营业成本和利 润。上述行为导致*ST 苏吴在 2020 年至 2023 年年度报告中分别虚增营业收入 露营业收入的 26.46%、26.39%、21.26%、16.82%；分别虚增营业成本 48,068.05 万元、44,823.70 万元、41,082.09 万元、35,544.47 万元，占当期披露营业成 本的 37.08%、35.47%、28.40%、20.95%；分别虚增利润总额 1,458.27 万元、 强制退市。 证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-083 江苏吴中医药发展股份有限公司关于公司股票 可能被实施重大违法强制退市的第六次风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 一、公司股票可能被实施重大违法强制退市风险暨立案调查进展情况 公司于 2 ...

公司指定信息披露媒体为《中国证券报》《上海证券报》以及上海证券交易 所网站（www.sse.com.cn），有关公司的信息均以上述指定媒体刊登的信息为准。 敬请投资者注意投资风险。 二、终止上市风险提示公告的披露情况 根据《股票上市规则》第 9.2.3 条第一款的规定：在上交所仅发行 A 股股票 或者 B 股股票的上市公司，首次出现股票收盘价低于 1 元的，应当在次一交易日 披露公司股票可能被终止上市的风险提示公告；出现连续 10 个交易日（不包含 公司股票停牌日）每日股票收盘价均低于 1 元的，应当在次一交易日披露公司股 票可能被终止上市的风险提示公告，其后每个交易日披露 1 次，直至公司股票收 盘价低于 1 元的情形消除或者出现终止上市情形之日止（以先达到的日期为准）。 根据《股票上市规则》第 9.6.1 条规定，交易类强制退市公司股票不进入退 市整理期交易。 三、其他事项 （处 罚字〔2025〕58 号），具体内容详见公司于 2025 年 7 月 14 日披露的《关于收 到中国证券监督管理委员会 <行政处罚事先告知书> 的公告》（公告编号：临 据中国证监会正式的处罚决定书结论，公司触及重大违法强制退市情 ...

Core Viewpoint - *ST Suwu's stock price has fallen below 1 yuan per share, triggering a delisting risk warning from the Shanghai Stock Exchange [1][3]. Group 1: Stock Performance and Delisting Risk - On August 14, *ST Suwu's stock closed at 0.99 yuan per share, which is below the 1 yuan threshold [1]. - According to the Shanghai Stock Exchange rules, if a company's stock price remains below 1 yuan for 20 consecutive trading days, it may face delisting [3]. - *ST Suwu has previously issued multiple warnings regarding potential delisting due to significant internal control issues [5]. Group 2: Regulatory Actions and Financial Reporting Issues - On July 13, *ST Suwu received a notice from the China Securities Regulatory Commission regarding administrative penalties, which could lead to a major violation delisting [5]. - The company has been found to have inflated revenue and profits through non-substantive trade activities with related companies, leading to false records in its annual reports from 2020 to 2023 [5]. - The 2024 financial report received an "unable to express an opinion" from the auditing firm, resulting in a delisting risk warning from the exchange [5]. Group 3: Related Party Transactions - On May 6, *ST Suwu announced that its controlling shareholder's related parties had occupied company funds, exceeding 5% of the latest audited net assets [6]. - This situation has led to additional risk warnings for the company's stock [6]. Group 4: Legal Disputes and Claims - On August 11, *ST Suwu's subsidiary, Datuo Medical, initiated arbitration against Regen Biotech for breach of contract, seeking 1.6 billion yuan in damages [8]. - The dispute centers around the exclusive distribution rights for the "AestheFill" product in China, which Regen attempted to revoke [9]. Group 5: Company Overview - *ST Suwu's main business includes pharmaceuticals and medical aesthetics, focusing on drug development and high-end aesthetic injection products [10]. - As of August 14, the company's stock price was 0.99 yuan, with a total market capitalization of 700 million yuan [10]. - As of the end of Q1 2025, *ST Suwu had approximately 86,200 shareholders, reflecting a significant increase from the previous quarter [12].

Core Viewpoint - *ST Suwu has issued a warning regarding the risk of delisting as its stock price has fallen below 1 RMB per share, closing at 0.99 RMB on August 14 [2][10]. Regulatory Compliance - According to the Shanghai Stock Exchange's listing rules, if a company's stock price remains below 1 RMB for 20 consecutive trading days, it may face delisting [4]. - *ST Suwu has previously issued multiple warnings about the potential for forced delisting due to significant legal violations [5][6]. Financial and Operational Issues - The company has been flagged for serious internal control issues, leading to a warning from the China Securities Regulatory Commission (CSRC) regarding potential major legal violations [6]. - *ST Suwu's subsidiaries have been involved in non-commercial trade activities that inflated revenue and profits, resulting in false financial reporting from 2020 to 2023 [6]. - The company's 2024 financial report received an "unable to express an opinion" from the auditing firm, prompting additional delisting risk warnings [6]. Shareholder Information - As of the end of Q1 2025, *ST Suwu had approximately 86,154 shareholders, reflecting a significant increase of 38.76% from the previous quarter [11][12]. Legal Disputes - *ST Suwu's subsidiary, Datuo Medical, has initiated arbitration against RegenBiotech, Inc. for breach of contract, seeking initial compensation of 1.6 billion RMB related to exclusive distribution rights for a product known as "AestheFill" [8][9].

Core Viewpoint - The acquisition of Regen Biotech, Inc. by Aimeike has led to a fierce commercial dispute with Jiangsu Wuzhong, the exclusive distributor of AestheFill in mainland China, following Regen's unilateral termination of the distribution agreement [1][2]. Group 1: Company Developments - Jiangsu Wuzhong announced that it has initiated arbitration against Regen after the latter revoked the exclusive distribution rights of AestheFill, with the arbitration case accepted on August 7, 2025 [1]. - Aimeike stated that it has not yet received any arbitration documents from the Shenzhen International Arbitration Court and will respond accordingly once received [1]. - Following the announcement of the dispute, Jiangsu Wuzhong's stock price fell by over 41% from 1.79 yuan per share to 1.04 yuan per share, while Aimeike's stock remained relatively stable [1]. Group 2: Historical Context - The exclusive distribution rights for AestheFill were granted to Jiangsu Wuzhong's subsidiary, Datou Medical, in August 2022, with the product approved for sale in mainland China in January 2024 [2]. - Aimeike's acquisition of control over Regen was completed on June 30, 2025, leading to the emergence of conflicts regarding the distribution agreement [2][3]. Group 3: Financial Implications - AestheFill has shown strong market performance, generating sales of 3.26 billion yuan in its first year and contributing significantly to Jiangsu Wuzhong's recovery, with a net profit of 70.48 million yuan in 2024, a 197.97% increase year-on-year [5][6]. - Jiangsu Wuzhong has invested over 400 million yuan in the clinical registration and market expansion of AestheFill, and the loss of distribution rights could severely impact its financial stability [6]. Group 4: Industry Insights - The dispute highlights the ongoing tension between brand owners and distributors in the medical aesthetics industry, where distributors often face uncertainties regarding their rights and the stability of their partnerships [7]. - The potential fallout from this dispute could lead to increased insecurity among distributors, which may negatively affect the marketing and sales performance of medical aesthetic products [7].

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-084 江苏吴中医药发展股份有限公司关于公司股票 可能存在因股价低于 1 元而终止上市的风险提示公告 二、终止上市风险提示公告的披露情况 根据《股票上市规则》第 9.2.3 条第一款的规定：在上交所仅发行 A 股股票 或者 B 股股票的上市公司，首次出现股票收盘价低于 1 元的，应当在次一交易日 披露公司股票可能被终止上市的风险提示公告；出现连续 10 个交易日（不包含 公司股票停牌日）每日股票收盘价均低于 1 元的，应当在次一交易日披露公司股 票可能被终止上市的风险提示公告，其后每个交易日披露 1 次，直至公司股票收 盘价低于 1 元的情形消除或者出现终止上市情形之日止（以先达到的日期为准）。 根据《股票上市规则》第 9.6.1 条规定，交易类强制退市公司股票不进入退 市整理期交易。 三、其他事项 2025 年 7 月 13 日，公司收到中国证监会下发的《行政处罚事先告知书》（处 罚字〔2025〕58 号），具体内容详见公司于 2025 年 7 月 14 日披露的《关于收 到中国证券监督管理委员会<行政处罚事先告知书>的公告》（公告编号 ...

一、公司股票可能被实施重大违法强制退市风险暨立案调查进展情况 公司于 2025 年 2 月 26 日收到中国证监会《立案告知书》（证监立案字 0392025006 号），因公司涉嫌信息披露违法违规，根据《中华人民共和国证券 江苏吴中医药发展股份有限公司(以下简称"公司")因涉嫌信息披露违 法违规，被中国证券监督管理委员会（以下简称"中国证监会"）立案 调查。2025 年 7 月 13 日，公司收到中国证监会下发的《行政处罚事先 告知书》（处罚字〔2025〕58 号）。认定公司虚增营业收入、营业成本 和利润，2020 年至 2023 年年度报告存在虚假记载。 如根据正式的处罚决定书结论，公司触及重大违法强制退市情形，公司 股票将被终止上市。根据《上海证券交易所股票上市规则》第 9.5.7 条、 第 9.5.8 条，如公司后续收到行政处罚决定书，显示公司触及重大违法 类强制退市情形，公司将申请停牌，并及时披露有关内容。上海证券交 易所将在停牌之日起的 5 个交易日内，向公司发出拟终止股票上市的事 先告知书，后续将根据《上海证券交易所股票上市规则》的相关规定， 作出是否终止公司股票上市的决定。 公司将全力配合中国证 ...

*ST苏吴还提示风险称，7月13日，公司收到中国证监会下发的《行政处罚事先告知书》，公司股票已 于7月14日起被叠加实施退市风险警示。如根据中国证监会正式的处罚决定书结论，公司触及重大违法 强制退市情形，公司股票将被终止上市。 北京商报讯（记者 丁宁）8月14日晚间，*ST苏吴（600200）发布公告称，公司股票8月14日收盘价为 0.99元/股，低于1元。根据《上海证券交易所股票上市规则》第9.2.1条第一款第一项规定，在上交所仅 发行A股股票的上市公司，如果连续20个交易日的每日股票收盘价均低于1元，公司股票可能被上交所 终止上市交易。 ...

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月14日，*ST苏吴（600200）发布公告称，公司股票当日 收盘价为0.99元/股，低于人民币1元。根据《上海证券交易所股票上市规则》中相关规定，如果连续20 个交易日的每日股票收盘价均低于1元，公司股票可能被上交所终止上市交易。 此前，因财务造假等问题，*ST苏吴股票已于2025年7月14日起被叠加实施退市风险警示。 ...

Core Viewpoint - The acquisition of Regen Biotech by Aimeike has led to a fierce commercial dispute with Jiangsu Wuzhong, the exclusive distributor of AestheFill in mainland China, following Regen's unilateral termination of the distribution agreement [1][3][4]. Group 1: Event Development - In August 2022, Dato Medical obtained exclusive distribution rights for AestheFill in mainland China, which was successfully launched in January 2024 [3]. - Aimeike announced its plan to acquire Regen in March 2025, completing the acquisition by June 30, 2025, which led to tensions regarding the distribution agreement [3][4]. - On July 21, 2025, Jiangsu Wuzhong received a termination notice from Regen, citing violations of the agreement by Dato Medical [3][4]. Group 2: Legal Actions and Financial Implications - Jiangsu Wuzhong has initiated arbitration proceedings against Regen, seeking to confirm the validity of the distribution agreement and claiming damages of 1.6 billion yuan [4][5]. - The dispute has negatively impacted Jiangsu Wuzhong's stock price, which fell over 41% since the termination notice, while Aimeike's stock remained relatively stable [1][4]. - Jiangsu Wuzhong reported a significant increase in net profit due to AestheFill sales, which accounted for 35.55% of its revenue in Q1 2025 [7][8]. Group 3: Market Dynamics and Industry Impact - AestheFill has shown strong market performance, generating 326 million yuan in sales in 2024 and contributing significantly to Jiangsu Wuzhong's recovery from previous losses [7][8]. - The ongoing dispute raises concerns about the stability of distribution agreements in the medical aesthetics industry, potentially affecting the confidence of distributors [9]. - Aimeike is facing pressure from slowing revenue growth, with a significant decline in its revenue and net profit growth rates from 2023 to 2024 [8][9].